20.54 USD
▲+0.14+0.69%
盘后 20.30 -1.15%
2026-09-15
市值
$1.33B
市盈率
—
EPS
-3.47
股息率
—
52 周区间
5.68 – 23.19
成交量
1.06M
Beta
0.02
目标价
32.36
52W 低 5.6852W 高 23.19
价格走势
公司简介
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysp...